Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHS 0214 open-label safety extension in rheumatoid arthritis and plaque psoriasis
2015-000665-30Phase 3Completed
- Sponsor
- Coherus BioSciences, Inc.
- Start
- May 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of etanercept in rheumatoid arthritis (RA) and plaque psoriasis (2 cohorts), sponsored by Coherus BioSciences, Inc. Primary endpoint: Safety. Started May 2015; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)plaque psoriasis
Beyond the preview
Go deeper on 2015-000665-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000665-30.